R-IT Regulatory Exclusivity Expiration is Dec 13, 2022 - that means FDA cannot accept an ANDA until then, and if one is filed it triggers an automatic 30 month stay. When patents expire is a totally different issue, and the earliest a R-IT patent expires is 2030, and longer than that in the EU. So I don't know what this is about, Hikma cannot challenge patents at this time - Hikma is defending charges that it's infringing on valid patents, not that the patents are invalid - that would take a separate court case that's almost 3 years away from even being allowed to be filed.